Stock Groups

Biogen posts much smaller-than-expected sales of new Alzheimer’s drug -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder

(Reuters) – Biogen Inc (NASDAQ:) reported a much smaller-than-expected quarterly sales of its Alzheimer’s drug Aduhelm on Wednesday, as the recently launched treatment faces sluggish uptake following scrutiny over its approval and a lack of clarity over coverage.

The company recorded $300,000 in sales of Aduhelm, priced at $56,000 a year, in the third quarter, compared to analysts’ average estimates of $10.79 million, according to Refinitiv data.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



[ad_2]